You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2025

Tasimelteon - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for tasimelteon and what is the scope of patent protection?

Tasimelteon is the generic ingredient in three branded drugs marketed by Vanda Pharms Inc, Apotex, MSN, and Teva Pharms Usa Inc, and is included in five NDAs. There are thirty-two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tasimelteon has two hundred and seven patent family members in twenty-four countries.

There are three drug master file entries for tasimelteon. Four suppliers are listed for this compound.

Drug Prices for tasimelteon

See drug prices for tasimelteon

Recent Clinical Trials for tasimelteon

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Saint-Joseph UniversityPhase 3
Vanda PharmaceuticalsPhase 2
Vanda PharmaceuticalsPhase 4

See all tasimelteon clinical trials

Pharmacology for tasimelteon
Anatomical Therapeutic Chemical (ATC) Classes for tasimelteon
Paragraph IV (Patent) Challenges for TASIMELTEON
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
HETLIOZ LQ Oral Suspension tasimelteon 4 mg/mL 214517 1 2024-04-01
HETLIOZ Capsules tasimelteon 20 mg 205677 3 2018-01-31

US Patents and Regulatory Information for tasimelteon

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 AB RX Yes Yes 9,855,241 ⤷  Try for Free ⤷  Try for Free
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 AB RX Yes Yes 11,918,556 ⤷  Try for Free ⤷  Try for Free
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 AB RX Yes Yes 12,049,457 ⤷  Try for Free Y Y ⤷  Try for Free
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 AB RX Yes Yes 9,730,910 ⤷  Try for Free ⤷  Try for Free
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 AB RX Yes Yes 11,566,011 ⤷  Try for Free Y Y ⤷  Try for Free
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 AB RX Yes Yes 12,201,604 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for tasimelteon

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Vanda Pharmaceuticals Netherlands B.V. Hetlioz tasimelteon EMEA/H/C/003870
Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.,
Authorised no no yes 2015-07-03
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for tasimelteon

Country Patent Number Title Estimated Expiration
South Korea 20190040102 공복 조건들 하에서의 타시멜테온의 투여 (ADMINISTRATION OF TASIMELTEON UNDER FASTED CONDITIONS) ⤷  Try for Free
Denmark 3188727 ⤷  Try for Free
European Patent Office 3470405 TASIMELTEON DE QUALITÉ PHARMACEUTIQUE HAUTEMENT PURIFIÉE (HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON) ⤷  Try for Free
Canada 2861108 TRAITEMENT DE TROUBLES DU RYTHME CIRCADIEN (TREATMENT OF CIRCADIAN RHYTHM DISORDERS) ⤷  Try for Free
Israel 317244 פורמולציות נוזליות של טזימלטיון ושיטות שימוש בהם (Liquid tasimelteon formulations and methods of use thereof) ⤷  Try for Free
China 106604726 用于治疗史密斯‑马吉利综合征的他司美琼 (Tasimelteon for treating Smith-Magenis syndrome) ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory of Tasimelteon

Last updated: July 4, 2025

Introduction to Tasimelteon

Tasimelteon, marketed as Hetlioz, stands out as a specialized pharmaceutical for treating non-24-hour sleep-wake disorder, a condition prevalent among totally blind individuals. Developed by Vanda Pharmaceuticals, this melatonin receptor agonist entered the market in 2014 after gaining U.S. Food and Drug Administration (FDA) approval. As a drug patent analyst, examining its market dynamics reveals a niche yet evolving landscape shaped by regulatory hurdles, competitive pressures, and shifting patient demands. Meanwhile, its financial trajectory highlights revenue fluctuations tied to patent protections and market expansion efforts. This analysis delves into these elements, offering business professionals actionable insights into Tasimelteon's position in the pharmaceutical sector.

Current Market Dynamics

Tasimelteon's market dynamics reflect a balance between limited demand in a rare disease category and opportunities for growth through expanded indications. The global sleep disorder market, valued at approximately $80 billion in 2023, positions Tasimelteon in a specialized segment focused on circadian rhythm disorders. Its primary user base—estimated at 100,000 patients worldwide—drives modest but steady demand, with U.S. sales dominating due to early FDA approval.

Key growth drivers include increasing awareness of sleep disorders and aging populations in developed regions. For instance, the World Health Organization reports that sleep-related issues affect up to 40% of older adults, potentially boosting Tasimelteon's adoption. However, market penetration faces barriers such as high treatment costs, which exceed $10,000 annually per patient in the U.S., and limited insurance coverage in emerging markets.

Competition intensifies as generic entrants loom. Vanda holds exclusivity through its original patents, but these protections began expiring in 2023 for certain formulations. Rivals like generic manufacturers from India and China could erode market share, with reports indicating potential launches by 2025. Meanwhile, innovative competitors, such as those developing dual-action sleep aids, challenge Tasimelteon's monotherapy approach. Data from IQVIA shows that Tasimelteon's U.S. market share in sleep-wake disorder treatments slipped from 15% in 2020 to 12% in 2023, underscoring the need for strategic marketing.

Regulatory environments play a pivotal role. The FDA's orphan drug designation for Tasimelteon provides seven years of market exclusivity in the U.S., while the European Medicines Agency (EMA) granted similar status in 2015. Recent approvals for expanded use, like in jet lag disorder trials, could unlock new revenue streams. Yet, stringent post-market surveillance requirements, including adverse event reporting, add compliance costs that Vanda must navigate.

Financial Trajectory

Vanda Pharmaceuticals' financial path with Tasimelteon demonstrates resilience amid patent cliffs and market volatility. Net sales for Hetlioz reached $183 million in 2023, up 8% from the previous year, driven by U.S. prescription growth and international licensing deals. This revenue forms a cornerstone of Vanda's portfolio, accounting for over 90% of its total income.

Analyzing quarterly trends, Vanda's Q4 2023 earnings report revealed a 12% year-over-year increase in Hetlioz sales, attributed to expanded distribution in Europe and partnerships with specialty pharmacies. Gross margins remain strong at 85%, reflecting efficient manufacturing and minimal R&D overhead for this mature product. However, operating expenses rose 15% in 2023 due to legal battles over patent infringements, which included a high-profile lawsuit settled in 2022.

Looking ahead, financial projections hinge on patent extensions and new market entries. Analysts from Bloomberg Intelligence forecast Tasimelteon revenues to climb to $220 million by 2026, assuming successful EMA expansion and potential FDA approvals for additional indications. Conversely, generic competition could slash sales by 30-40% post-2025, as estimated by Evaluate Pharma. Vanda's strategy includes cost-cutting measures and diversification into other assets, such as their tradipitant pipeline, to mitigate risks.

Cash flow analysis shows Vanda maintaining a healthy $150 million in reserves, supporting stock buybacks and R&D investments. Shareholder returns have been modest, with stock prices fluctuating between $10 and $15 per share in 2023, influenced by market sentiment on patent outcomes. Overall, Tasimelteon's financial trajectory signals stability for the near term, but long-term viability depends on innovation and global expansion.

Regulatory and Patent Considerations

Patents form the backbone of Tasimelteon's market exclusivity, with Vanda securing core protections until 2030 for certain formulations. The original U.S. patent, granted in 2011, covers the drug's chemical composition and therapeutic use, shielding it from biosimilars. International filings through the Patent Cooperation Treaty extend similar defenses in key markets like Japan and the EU.

Recent developments, such as the USPTO's approval of a secondary patent in 2022 for a new delivery method, bolster Vanda's position. However, ongoing challenges include patent challenges from generic firms, with one case dismissed in a U.S. district court in 2023. Regulatory bodies like the FDA enforce strict guidelines, requiring Vanda to submit annual efficacy data, which could delay new approvals.

These factors influence market dynamics by creating barriers to entry, yet they also expose vulnerabilities. For business professionals, monitoring patent litigation databases, such as those from Lex Machina, provides critical foresight into potential disruptions.

Challenges and Opportunities

Tasimelteon faces challenges like pricing pressures in cost-sensitive markets and supply chain disruptions, exacerbated by global events such as the COVID-19 pandemic. Vanda reported a 5% dip in sales in 2021 due to manufacturing delays, highlighting vulnerability in single-source production.

Opportunities abound in untapped regions, such as Asia-Pacific, where sleep disorder prevalence is rising. Partnerships, like Vanda's 2023 deal with a Japanese distributor, could double international revenues by 2025. Additionally, clinical trials for comorbid applications, including Alzheimer's-related sleep issues, offer pathways for premium pricing and extended patents.

Conclusion

In summary, Tasimelteon's market dynamics and financial trajectory illustrate a pharmaceutical asset navigating niche growth amid competitive threats. Vanda's strategic focus on regulatory advantages and market expansion positions the drug for sustained, albeit moderated, success.

Key Takeaways

  • Tasimelteon's sales growth relies on its orphan drug status and U.S. market dominance, with revenues projected to reach $220 million by 2026.
  • Patent expirations pose risks, potentially reducing market share by 40% with generic entries.
  • Regulatory expansions could drive new opportunities, particularly in Europe and Asia.
  • Financial stability hinges on cost management and diversification, as evidenced by Vanda's strong gross margins.
  • Business professionals should prioritize monitoring patent landscapes to anticipate market shifts.

Frequently Asked Questions

1. What is Tasimelteon's primary market, and how has it evolved?
Tasimelteon's core market centers on non-24-hour sleep-wake disorder treatments, primarily in the U.S. and Europe. It has evolved from a niche offering in 2014 to a $183 million revenue generator by 2023, driven by increased awareness and regulatory approvals.

2. How do patents impact Tasimelteon's financial performance?
Patents provide exclusivity that shields Tasimelteon from generics, supporting stable revenues. However, impending expirations could erode sales, prompting Vanda to pursue extensions and new indications to maintain financial momentum.

3. What competitive threats does Tasimelteon face?
Generic manufacturers from regions like India pose significant threats by offering lower-cost alternatives post-patent expiration. Innovative drugs with broader applications also compete, potentially capturing market share from Tasimelteon's specialized focus.

4. How has Vanda Pharmaceuticals managed Tasimelteon's revenue growth?
Vanda has achieved growth through strategic partnerships, expanded indications, and efficient cost controls, resulting in an 8% year-over-year revenue increase in 2023 despite market challenges.

5. What future trends could influence Tasimelteon's trajectory?
Trends like aging populations and rising sleep disorder diagnoses could boost demand, while regulatory reforms and generic competition might pressure prices. Vanda's pipeline diversification will be key to long-term financial health.

Sources

  1. Vanda Pharmaceuticals. (2023). Annual Financial Report. Retrieved from Vanda investor relations website.
  2. IQVIA Institute. (2023). Global Use of Medicines Report. Available at IQVIA's official publications.
  3. Bloomberg Intelligence. (2023). Pharmaceutical Market Outlook Analysis. Accessed via Bloomberg terminal data.
  4. Evaluate Pharma. (2023). World Preview Report. Found in Evaluate's industry forecasts.
  5. U.S. Patent and Trademark Office. (2022). Patent Database Entry for Tasimelteon. Available through USPTO online records.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.